SWOG 1826-A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

January 06, 2020
https://clinicaltrials.gov/ct2/show/NCT03907488
Cancer - Lymphoma
Principal Investigator: Ding Wang, MD
Advanced classical Hodgkin lymphoma, advanced Hodgkin lymphoma, newly diagnosed Hodgkin lymphoma
Accepting Participants
313-844-7794